Biomet had another suitor; Colon cancer Dx lowers healthcare costs;

@FierceMedDev: ICYMI: ReWalk squeaks by with $36M IPO as oncology device player Mevion files to raise up to $69M. Article | Follow @FierceMedDev

@MichaelGFierce: HIV-fighting intravaginal ring research nets $20M from NIH. FierceDrugDelivery story | Follow @MichaelGFierce

> A study to be published in Fertility & Sterility found that the EmbryoScope time-lapse system significantly benefited reproduction rates. Release

> Biomet CEO, Jeffrey Binder met with "company A's" CEO in December 2013 to discuss a potential merger, before deciding to accept Zimmer's offer in 2014. Story

> Genomic Health's Oncotype DX colon cancer test may result in a significant reduction in direct medical costs, according to an economic analysis published in PharmacoEconomics. Release

> The smartphone sensor-powered Phone Oximeter pulse oximeter is a low-cost Sepsis monitoring system aiming to reduce deaths in the developing world for patients with sepsis, children with pneumonia, and women with preeclampsia. Release

Biotech News

@FierceBiotech: Arch, Polaris back a $20M round for Scholar Rock's immune system R&D platform. Article | Follow @FierceBiotech

@JohnCFierce: This "drug" is what gives biotech a bad name--simply awful. | Follow @JohnCFierce

@DamianFierce: ICYMI: $BIIB and $ABBV plan to market the monthly MS shot daclizumab as Zinbryta, filing in 2015. Release | Follow @DamianFierce

@EmilyMFierce: Well, this is an interesting development. Nature reviewers not persuaded by initial stem cell papers. More from Science | Follow @EmilyMFierce

> Avanir skyrockets as its controversial generic combo claims a hit in PhII Alzheimer's study. Report

> Cancer R&D stars pitch an $86M biotech IPO for Kolltan Pharma. Story

> Roche's Genentech triggers its PhIII program for blockbuster AMD contender. News

Pharma News

@FiercePharma: Tops in FP this weekend: Analysts: Pfizer execs say they're locked-and-loaded on tax inversion, and open to targets. Article | Follow @FiercePharma

@EricPFierce: Apotex, which has had plenty of cGMP issues of its own, is recalling generic Paxil made at GSK plant. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. To get it every week, subscribe here. | Follow @CarlyHFierce

> Balky payers, beware: Gilead eyes $95K-or-so price for Sovaldi combo pill. Article

> Salix hands off Relistor, other drugs to Lupin in Canada. News

> Mylan, Ranbaxy, others to bring cheap Sovaldi to 91 markets. Story

CRO News

> Evotec signs a Huntington's deal as diabetes project falls through. Report

> Quintiles homes in on small biotechs with new service offering. More

> Recruitment specialist Trialbee snags a deal with AstraZeneca. Item

> Icon and Medidata unite to give patients a louder voice in clinical trials. Article

> PRA swings for $375M in the next big CRO IPO. News

Biotech IT News

> Wearables project aims to provide new source of data for MS trials. Story

> Application of regulatory handbrake to 23andMe offers cautionary tale to Silicon Valley. Report

> NCI turns to Dell for pediatric cancer research project. More

> AstraZeneca taps Trialbee for online patient recruitment. Article

> Mayo Clinic to apply IBM's Watson to matching patients to trials. Story

Animal Health News

> FDA seeks input on conditional approvals for new animal health products. Report

> Merck launches new vaccine to fight PRRS in pig herds. More

> European Commission adds new proposals for use of veterinary meds and medicated feed. Story

> Alivira snaps up 60% stake in Turkey's Provet Veterinary Products. Article

> Dechra Pharmaceuticals reports gains in full-year profit. Report

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.